Cyclacel Pharmaceuticals Inc CYCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYCC is a good fit for your portfolio.
News
-
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
-
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
-
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
-
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
Trading Information
- Previous Close Price
- $2.30
- Day Range
- $1.67–1.97
- 52-Week Range
- $1.57–12.60
- Bid/Ask
- $1.66 / $1.67
- Market Cap
- $2.24 Mil
- Volume/Avg
- 2.4 Mil / 50,013
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://cyclacel.com
Valuation
|
Metric
|
CYCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.01 |
Price/Sales | 4.66 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYCC
|
|---|---|
Quick Ratio | 0.87 |
Current Ratio | 0.91 |
Interest Coverage | — |
Quick Ratio
CYCC
Profitability
|
Metric
|
CYCC
|
|---|---|
Return on Assets (Normalized) | −120.97% |
Return on Equity (Normalized) | −214.22% |
Return on Invested Capital (Normalized) | −215.11% |
Return on Assets
CYCC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dlbcydqq | Xxbb | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zrrhwgy | Pfxfgh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rrpznrnv | Dytdvv | $99.5 Bil | |
MRNA
| Moderna Inc | Zhfjxnh | Vxfc | $38.8 Bil | |
ARGX
| argenx SE ADR | Vyjkzpnn | Pknz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kzzhrnxv | Vypl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kvfztlx | Lzcwcf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tvqsykkqg | Sysvvn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cgdznsndbx | Glywg | $12.5 Bil | |
INCY
| Incyte Corp | Ndspjzkm | Skbxq | $11.6 Bil |